


Prevention Suite and eHD Technology will be the Esaote's keys to change the role of Cardiovascular Ultrasound at the incoming ESC 2013

Genoa, August 30th 2013 –

At the next ESC 2013, European Congress of Cardiology (Amsterdam, The Netherlands 31 August-04 September, 2013) Esaote showcases Prevention Suite and eHD Technology as key solutions to change the role of Cardiovascular Ultrasound imaging.

Cardiovascular diseases are the leading causes of death and disability in the world. Out of the total death, heart attacks are responsible for 42% and strokes were responsible for 35% in 2008, according to Global Atlas on Cardiovascular Diseases Prevention and Control. In the US, the average is 1 death every 38 seconds. While cardiovascular diagnosis is getting more and more precise every day, cardiovascular diseases continue to rise because preventive measures are inadequate.



“To prevent heart attacks and strokes, the total cardiovascular risk needs to be reduced” said Dr. Fausto Rigo, Head of Cardiac Diagnostic Imaging Department, Dell’Angelo Hospital, Mestre-Venice (Italy). “Atherosclerosis is one of the highest impact factors that remains asymptomatic for decades. The integration of heart-vessel study could draw a new roadmap to early and personalized cardiovascular diseases risk assessment”.

Esaote’s Prevention Suite offers dedicated tools to perform this study, by providing quick and reliable measurement of carotid intima media thickness and arterial stiffness, together with cardiac deformation indexes and coronary flow quantification.

“Prevention Suite in combination with the eHD Technology represent the latest Esaote’s breakthrough in cardiovascular ultrasound imaging” - said Marco Maglione, Cardiovascular Product Manager at Esaote - “The complete reengineering of image capturing, processing and displaying meets the most advanced features to provide comprehensive clinical outcomes, improved patient care and cost-effectiveness”.

During the next ESC 2013, Esaote will showcase also **MyLab™Twice**, **MyLab™Alpha**, **MyLab™Seven** and **MyLab™One Vascular**, a wide range of ultrasound solutions to satisfy any cardiovascular clinical setting.

Visit us at **BOOTH B325** and get the latest updates about innovative ultrasound systems and advanced technologies dedicated to cardiovascular clinical practice.

With about 327 millions euro consolidated sales (70% of which coming from the international markets) the Esaote Group is leader in the sector of biomedical equipment (in particular, ultrasound, dedicated magnetic resonance and software to manage the diagnostic process). Today Esaote gives work to over 1360 employees, 20% of which employed in the R&D activities. Esaote is present with its industrial and research units in Italy (Genoa, Florence, Naples) in the Netherlands (Maastricht), and in China (Shenzhen). Esaote is internationally recognized to be one of the "Top Ten" world's leading diagnostic imaging companies. Esaote S.p.A. is owned by Ares (39,8%), IMI Investimenti of Intesa Sanpaolo Group (19,2%), Equinox (13,2%), MP Venture (13,2%), Carige (8,2%) and by 100 managers and directors of the Group (6.4%).

Information concerning Esaote and its products are available on the Internet site at the address <http://www.esaote.com>

XStrain™4D is not yet for sales in the USA.

Technology and features are system/configuration dependent. Specifications subject to change without notice. Information might refer to products or modalities not yet approved in all countries. For further details, please contact your Esaote sales representative.